MX2020004202A - Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas. - Google Patents

Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas.

Info

Publication number
MX2020004202A
MX2020004202A MX2020004202A MX2020004202A MX2020004202A MX 2020004202 A MX2020004202 A MX 2020004202A MX 2020004202 A MX2020004202 A MX 2020004202A MX 2020004202 A MX2020004202 A MX 2020004202A MX 2020004202 A MX2020004202 A MX 2020004202A
Authority
MX
Mexico
Prior art keywords
phenyl
substituted phenyl
thiones
triazole thiones
sulfonyl
Prior art date
Application number
MX2020004202A
Other languages
English (en)
Inventor
Emily M Stocking
Srinivasa Reddy Natala
Wolfgang J Wrasidlo
Diana Luz Price
Original Assignee
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropore Therapies Inc filed Critical Neuropore Therapies Inc
Publication of MX2020004202A publication Critical patent/MX2020004202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se relaciona a fenil sulfonil fenil triazol tionas sustituidas, composiciones farmacéuticas que contienen las mismas y métodos para utilizarlas.
MX2020004202A 2017-10-30 2018-10-29 Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas. MX2020004202A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579070P 2017-10-30 2017-10-30
US201762584630P 2017-11-10 2017-11-10
PCT/US2018/058050 WO2019089478A1 (en) 2017-10-30 2018-10-29 Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof

Publications (1)

Publication Number Publication Date
MX2020004202A true MX2020004202A (es) 2020-08-13

Family

ID=66333645

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004202A MX2020004202A (es) 2017-10-30 2018-10-29 Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas.

Country Status (12)

Country Link
US (4) US10501423B2 (es)
EP (1) EP3703675A4 (es)
JP (2) JP7277473B2 (es)
KR (1) KR102639231B1 (es)
CN (1) CN111372579B (es)
AU (1) AU2018359224B2 (es)
BR (1) BR112020008727A2 (es)
CA (1) CA3080578A1 (es)
IL (1) IL274010B2 (es)
MX (1) MX2020004202A (es)
SG (1) SG11202003879RA (es)
WO (1) WO2019089478A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008727A2 (pt) 2017-10-30 2020-10-20 Neuropore Therapies, Inc. fenil sulfonil fenil triazol tionas substituídas e usos destas
WO2019246454A1 (en) * 2018-06-20 2019-12-26 Neuropore Therapies, Inc. Method of treating a condition associated with neurodegeneration using inhibitors of oat3
CN117384029B (zh) * 2023-12-12 2024-02-20 山东国邦药业有限公司 一种2,4,5-三氟苯乙酸的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
US4279637A (en) 1979-06-02 1981-07-21 Velsicol Chemical Corporation Herbicidal N-substituted 4-imidazolin-2-ones
DE3307506A1 (de) 1983-03-03 1984-09-06 Agfa-Gevaert Ag, 5090 Leverkusen Fotografisches aufzeichnungsmaterial mit inhibitorvorlaeuferverbindungen
US5108486A (en) * 1990-02-09 1992-04-28 Kanagawa Chemical Laboratory, Ltd. Herbicidal substituted-phenyl-1,2,4-triazol-5(1H)-thiones and -ones
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
DE10123586A1 (de) 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
US20020183306A1 (en) 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
RU2223952C2 (ru) 2001-06-04 2004-02-20 Институт физиологически активных веществ РАН Производные n,s-замещенных n'-1-[(гетеро)арил]-n'-[(гетеро)арил]метилизотиомочевин или их солей с фармакологически приемлемыми кислотами нх, способы получения их солей и оснований, фармацевтическая композиция, способ лечения и способ изучения глутаматэргической системы
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
KR100768609B1 (ko) 2003-07-09 2007-10-18 에프. 호프만-라 로슈 아게 티오페닐아미노이미다졸린
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
US20050228031A1 (en) 2004-04-13 2005-10-13 Bilodeau Mark T Tyrosine kinase inhibitors
US7008748B1 (en) * 2004-09-07 2006-03-07 Eastman Kodak Company Silver salt-toner co-precipitates and imaging materials
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US20060217390A1 (en) 2005-02-24 2006-09-28 Esmir Gunic Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
US20060276464A1 (en) 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
CA2614098A1 (en) 2005-07-04 2007-01-11 Dr. Reddy's Laboratories Ltd. Thiazoles derivatives as ampk activator
RS53981B1 (sr) 2006-03-24 2015-10-30 Array Biopharma Inc. Analozi 2-aminopiridina kao aktivatori glukokinaze
MX2009004947A (es) 2006-11-09 2009-05-19 Hoffmann La Roche Arilsulfonil-pirrolidinas como inhibidores 5-hidroxitriptaminas6 (5-ht6).
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
JP5450108B2 (ja) 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての２−アミノピリジン類似体
EA019104B1 (ru) 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9271962B2 (en) 2008-03-17 2016-03-01 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
KR102142753B1 (ko) 2009-03-27 2020-09-14 히타치가세이가부시끼가이샤 열경화성 수지 조성물, 및 이를 이용한 프리프레그, 지지체 부착 절연 필름, 적층판 및 인쇄 배선판
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス，インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN106986856A (zh) 2010-09-03 2017-07-28 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
US20140044813A1 (en) 2012-08-09 2014-02-13 Kemin Industries, Inc. Plant Extracts for Improving Cognitive Health and Function
JP2015524483A (ja) * 2012-08-09 2015-08-24 ニューロポア セラピーズ，インコーポレイティド Ｐｉ３−キナーゼシグナリング経路の調節因子としてのアリール及びヘテロアリールで置換されたベンゼン誘導体
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
BR112020008727A2 (pt) 2017-10-30 2020-10-20 Neuropore Therapies, Inc. fenil sulfonil fenil triazol tionas substituídas e usos destas

Also Published As

Publication number Publication date
WO2019089478A1 (en) 2019-05-09
AU2018359224A1 (en) 2020-06-18
JP7277473B2 (ja) 2023-05-19
US20230391734A1 (en) 2023-12-07
US20210300881A1 (en) 2021-09-30
US20200123116A1 (en) 2020-04-23
AU2018359224B2 (en) 2023-10-05
IL274010A (en) 2020-05-31
US10501423B2 (en) 2019-12-10
JP2023100842A (ja) 2023-07-19
BR112020008727A2 (pt) 2020-10-20
CA3080578A1 (en) 2019-05-09
US11008294B2 (en) 2021-05-18
JP2021501202A (ja) 2021-01-14
US20190292158A1 (en) 2019-09-26
KR20200083545A (ko) 2020-07-08
CN111372579B (zh) 2023-08-22
EP3703675A1 (en) 2020-09-09
SG11202003879RA (en) 2020-05-28
US11708338B2 (en) 2023-07-25
IL274010B1 (en) 2023-03-01
KR102639231B1 (ko) 2024-02-22
CN111372579A (zh) 2020-07-03
EP3703675A4 (en) 2021-06-16
IL274010B2 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
CO2020007244A2 (es) Inhibidores de kras g12c
PH12020550703A1 (en) Sulfonamide compounds and use thereof
CO2017000064A2 (es) Compuestos de [1,2,4]triazol sustituido
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
BR112018070568A2 (pt) derivados de oxadiazol microbiocidas
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
MX2017002295A (es) Composiciones que comprenden una caseína y métodos para producir las mismas.
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
CU20180027A7 (es) DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
ECSP13012877A (es) FORMAS SÓLIDAS SDE 3- (5-AMINO-2-metil -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, Y SUS COMPOSICIONES FARMACÉUTICAS Y USOS
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
BR112018008467A2 (pt) derivados de oxadiazol microbiocidas
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
BR112018012825A2 (pt) derivados de oxadiazol microbiocidas
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2018003297A (es) Aplicador de precision.
BR112018002983A2 (pt) composição compreendendo uma lactama e um álcool
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
CL2018001493A1 (es) Nuevos derivados de fenilo
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen